Table 1.
Comparison of baseline patient characteristics of CLOT, CATCH, Hokusai Cancer VTE, Select‐D, and Daltecan study
| Study | CLOT4 | CATCH33 | Hokusai VTE Cancer45 | Select‐D47 | Daltecan50 , a |
|---|---|---|---|---|---|
| N | 676 | 900 | 1046 | 406 | 334 |
| Age, years (mean) | 62.5 | 59.2 | 64 | 67 (median) | 63.8 |
| Male | 51.5% | 40.6% | 51.6% | 51% | 48.8% |
| Solid tumor | 89.6% | 89.6% | 89.1% | 97% | 91.6% |
| Metastatic disease | 67.3% | 54.7% | 59% | 59% | 62.6% |
| ECOG ≥ 2 | 36.7% | 23.2% | 23.8% | 23.5% | 21% |
| Cancer treatment at randomization | 77.7% | 52.9% | 72.4% | 69% | N/A |
| Incidental | 0% | 0% | 32.5% | 53% | N/A |
| History of VTE | 11% | 6.3% | 10.7% | N/A | N/A |
ECOG, Eastern Cooperative Oncolology Group performance status; N, total number of patients enrolled; N/A, not available; VTE, venous thromboembolism.
a
Daltecan study is the only nonrandomized prospective cohort study included here.